Neon Therapeutics, Inc. (NTGN) SEC Filing 8-K Material Event for the period ending Tuesday, May 5, 2020

Neon Therapeutics, Inc.

CIK: 1694187 Ticker: NTGN

View differences made from one to another to evaluate Neon Therapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Neon Therapeutics, Inc..


Assess how Neon Therapeutics, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Neon Therapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2020 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools
Ticker: NTGN
CIK: 1694187
Form Type: 8-K Corporate News
Accession Number: 0001694187-20-000044
Submitted to the SEC: Tue May 05 2020 5:09:42 PM EST
Accepted by the SEC: Tue May 05 2020
Period: Tuesday, May 5, 2020
Industry: Biological Products No Disgnostic Substances
  1. Vote of Security Holders

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: